MSI-High Colorectal Cancer: ASCO Tumor Boards

This is a case-based activity that includes discussion of a 45-year-old man who presents with right lower quadrant abdominal pain. CT imaging showed suspected diverticulitis but no metastatic disease and he was treatment with empiric antibiotics. After completion of antibiotics, he underwent a colonoscopy which revealed a 4-mm tubular adenoma in the transverse colon and a mass in the cecum biopsy which confirms poorly differentiated invasive adenocarcinoma.  

Learning Objectives

  • Discuss the epidemiology, histopathologic characteristics, and diagnosis of microsatellite instability (MSI) and DNA mismatch repair enzyme deficiency (dMMR) in patients with colorectal cancer
  • Differentiate hereditary and sporadic MSI-high colorectal cancer
  • Evaluate the prognostic implications of MSI-high status in stage II colon cancer patients and the impact of MSI-high status on efficacy of adjuvant chemotherapy in these patients
  • Identify and apply novel therapeutic approaches, including immunotherapy, for patients with MSI-high colorectal cancer

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • 1 AMA PRA Category 1 Credits™ 
  • ABIM MOC Points
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.

Important Notes

  • This course expires on April 20, 2019. Participants must complete all necessary course components by this date.
  • This course is available as part of the 2016 ASCO Tumor Boards bundle.